Literature DB >> 20374945

Diabetic kidney disease: act now or pay later.

Robert C Atkins, Paul Zimmet.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20374945     DOI： 10.1016/j.jash.2009.12.001

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN： 1878-7436


× No keyword cloud information.
  3 in total

1.  NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.

Authors:  Li Zhang; Ruizhao Li; Wei Shi; Xinling Liang; Shuangxin Liu; Zhiming Ye; Chunping Yu; Yuanhan Chen; Bin Zhang; Wenjian Wang; Yuxiong Lai; Jianchao Ma; Zhuo Li; Xiaofan Tan
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

2.  Heparanase is essential for the development of diabetic nephropathy in mice.

Authors:  Natali Gil; Rachel Goldberg; Tzahi Neuman; Marjolein Garsen; Eyal Zcharia; Ariel M Rubinstein; Toin van Kuppevelt; Amichay Meirovitz; Claudio Pisano; Jin-Ping Li; Johan van der Vlag; Israel Vlodavsky; Michael Elkin
Journal:  Diabetes       Date:  2011-11-21       Impact factor: 9.461

3.  Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress.

Authors:  Zeng Si Wang; Fei Xiong; Xiao Hang Xie; Dan Chen; Jian Hua Pan; Li Cheng
Journal:  BMC Nephrol       Date:  2015-03-31       Impact factor: 2.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.